-
1
-
-
84857621736
-
Inhaled colistin for lower respiratory tract infections
-
Antoniu S.A., Cojocaru I. Inhaled colistin for lower respiratory tract infections. Expert Opin. Drug Deliv. 2012, 9:333-342.
-
(2012)
Expert Opin. Drug Deliv.
, vol.9
, pp. 333-342
-
-
Antoniu, S.A.1
Cojocaru, I.2
-
3
-
-
70249104706
-
Delivery of antibiotics to the respiratory tract: an update
-
Traini D., Young P.M. Delivery of antibiotics to the respiratory tract: an update. Expert Opin. Drug Deliv. 2009, 6:897-905.
-
(2009)
Expert Opin. Drug Deliv.
, vol.6
, pp. 897-905
-
-
Traini, D.1
Young, P.M.2
-
4
-
-
84884254267
-
Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections
-
Yapa S.W.S., Li J., Porter C.J.H., Nation R.L., Patel K., McIntosh M.P. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob. Agents Chemother. 2013, 57:5087-5095.
-
(2013)
Antimicrob. Agents Chemother.
, vol.57
, pp. 5087-5095
-
-
Yapa, S.W.S.1
Li, J.2
Porter, C.J.H.3
Nation, R.L.4
Patel, K.5
McIntosh, M.P.6
-
5
-
-
79959248672
-
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients
-
Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., Silveira F.P., Forrest A., Nation R.L. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 2011, 55:3284-3294.
-
(2011)
Antimicrob. Agents Chemother.
, vol.55
, pp. 3284-3294
-
-
Garonzik, S.M.1
Li, J.2
Thamlikitkul, V.3
Paterson, D.L.4
Shoham, S.5
Jacob, J.6
Silveira, F.P.7
Forrest, A.8
Nation, R.L.9
-
6
-
-
84875215401
-
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
-
Schuster A., Haliburn C., Döring G., Goldman M.H., Freedom Study Group Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013, 68:344-350.
-
(2013)
Thorax
, vol.68
, pp. 344-350
-
-
Schuster, A.1
Haliburn, C.2
Döring, G.3
Goldman, M.H.4
-
7
-
-
84898634072
-
Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration
-
Yapa S.W.S., Li J., Patel K., Wilson J.W., Dooley M.J., George J., Clark D., Poole S., Williams E., Porter C.J.H., Nation R.L., McIntosh M.P. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob. Agents Chemother. 2014, 58:2570-2579.
-
(2014)
Antimicrob. Agents Chemother.
, vol.58
, pp. 2570-2579
-
-
Yapa, S.W.S.1
Li, J.2
Patel, K.3
Wilson, J.W.4
Dooley, M.J.5
George, J.6
Clark, D.7
Poole, S.8
Williams, E.9
Porter, C.J.H.10
Nation, R.L.11
McIntosh, M.P.12
-
8
-
-
84908259448
-
Emerging inhalation aerosol devices and strategies: where are we headed?
-
Zhou Q., Tang P., Leung S.S.Y., Chan J.G.Y., Chan H.-K. Emerging inhalation aerosol devices and strategies: where are we headed?. Adv. Drug Deliv. Rev. 2014, 75:3-17.
-
(2014)
Adv. Drug Deliv. Rev.
, vol.75
, pp. 3-17
-
-
Zhou, Q.1
Tang, P.2
Leung, S.S.Y.3
Chan, J.G.Y.4
Chan, H.-K.5
-
9
-
-
84930085610
-
Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead
-
Velkov T., Nusaibah A.R., Zhou Q., Chan H.-K., Li J. Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv. Drug Deliv. Rev. 2014.
-
(2014)
Adv. Drug Deliv. Rev.
-
-
Velkov, T.1
Nusaibah, A.R.2
Zhou, Q.3
Chan, H.-K.4
Li, J.5
-
10
-
-
84890469602
-
Inhaled antibiotics to treat lung infection
-
Cipolla D., Chan H.-K. Inhaled antibiotics to treat lung infection. Pharm. Patent Anal. 2013, 2:647-663.
-
(2013)
Pharm. Patent Anal.
, vol.2
, pp. 647-663
-
-
Cipolla, D.1
Chan, H.-K.2
-
11
-
-
70349096824
-
Emerging treatments in cystic fibrosis
-
Jones A.M., Helm J.M. Emerging treatments in cystic fibrosis. Drugs 2009, 69:1903-1910.
-
(2009)
Drugs
, vol.69
, pp. 1903-1910
-
-
Jones, A.M.1
Helm, J.M.2
-
12
-
-
79953262396
-
Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
-
Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011, 9.
-
(2011)
BMC Med.
, vol.9
-
-
Hoiby, N.1
-
13
-
-
84902343133
-
Delivery of inhalation drugs to children for asthma and other respiratory diseases
-
Kwok P.C.L., Chan H.-K. Delivery of inhalation drugs to children for asthma and other respiratory diseases. Adv. Drug Deliv. Rev. 2014, 73:83-88.
-
(2014)
Adv. Drug Deliv. Rev.
, vol.73
, pp. 83-88
-
-
Kwok, P.C.L.1
Chan, H.-K.2
-
14
-
-
1242351697
-
Comparison of lung deposition in two types of nebulization - intrapulmonary percussive ventilation vs jet nebulization
-
Reychler G., Keyeux A., Cremers C., Veriter C., Rodenstein D.O., Liistro G. Comparison of lung deposition in two types of nebulization - intrapulmonary percussive ventilation vs jet nebulization. Chest 2004, 125:502-508.
-
(2004)
Chest
, vol.125
, pp. 502-508
-
-
Reychler, G.1
Keyeux, A.2
Cremers, C.3
Veriter, C.4
Rodenstein, D.O.5
Liistro, G.6
-
15
-
-
69549124208
-
Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization
-
Qi A.S., Friend J.R., Yeo L.Y., Morton D.A.V., McIntosh M.P., Spiccia L. Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization. Lab Chip 2009, 9:2184-2193.
-
(2009)
Lab Chip
, vol.9
, pp. 2184-2193
-
-
Qi, A.S.1
Friend, J.R.2
Yeo, L.Y.3
Morton, D.A.V.4
McIntosh, M.P.5
Spiccia, L.6
-
16
-
-
84901692006
-
Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization
-
Rajapaksa A.E., Ho J.J., Qi A., Bischof R., Nguyen T.H., Tate M., Piedrafita D., McIntosh M.P., Yeo L.Y., Meeusen E., Coppel R.L., Friend J.R. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir. Res. 2014, 15:60.
-
(2014)
Respir. Res.
, vol.15
, pp. 60
-
-
Rajapaksa, A.E.1
Ho, J.J.2
Qi, A.3
Bischof, R.4
Nguyen, T.H.5
Tate, M.6
Piedrafita, D.7
McIntosh, M.P.8
Yeo, L.Y.9
Meeusen, E.10
Coppel, R.L.11
Friend, J.R.12
-
17
-
-
77950620340
-
Mode of breathing-tidal or slow and deep-through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of (99m) Tc-DTPA
-
Nikander K., Prince I., Coughlin S., Warren S., Taylor G. Mode of breathing-tidal or slow and deep-through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of (99m) Tc-DTPA. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl. 1):S37-S43.
-
(2010)
J. Aerosol Med. Pulm. Drug Deliv.
, vol.23
, pp. S37-S43
-
-
Nikander, K.1
Prince, I.2
Coughlin, S.3
Warren, S.4
Taylor, G.5
-
18
-
-
79954515565
-
Personalizing aerosol medicine: development of delivery systems tailored to the individual
-
Cipolla D., Chan H.K., Schuster J., Farina D. Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther. Deliv. 2010, 1:667-682.
-
(2010)
Ther. Deliv.
, vol.1
, pp. 667-682
-
-
Cipolla, D.1
Chan, H.K.2
Schuster, J.3
Farina, D.4
-
19
-
-
34247193128
-
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety
-
Geller D.E., Konstan M.W., Noonberg S.B., Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 2007, 42:307-313.
-
(2007)
Pediatr. Pulmonol.
, vol.42
, pp. 307-313
-
-
Geller, D.E.1
Konstan, M.W.2
Noonberg, S.B.3
Conrad, C.4
-
20
-
-
78651412529
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial
-
Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., Zhang J., Angyalosi G., He E., Geller D.E. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011, 10:54-61.
-
(2011)
J. Cyst. Fibros.
, vol.10
, pp. 54-61
-
-
Konstan, M.W.1
Flume, P.A.2
Kappler, M.3
Chiron, R.4
Higgins, M.5
Brockhaus, F.6
Zhang, J.7
Angyalosi, G.8
He, E.9
Geller, D.E.10
-
21
-
-
84930091063
-
Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF)
-
M.J. Harrison, M. McCarthy, C. Fleming, C. Hickey, C. Shortt, J.A. Eustace, D.M. Murphy, B.J. Plant, Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF), Journal of Cystic Fibrosis.
-
Journal of Cystic Fibrosis
-
-
Harrison, M.J.1
McCarthy, M.2
Fleming, C.3
Hickey, C.4
Shortt, C.5
Eustace, J.A.6
Murphy, D.M.7
Plant, B.J.8
-
22
-
-
34250341797
-
Microbial contamination of nebulizers in the home treatment of cystic fibrosis
-
Blau H., Mussaffi H., Zahav M.M., Prais D., Livne M., Czitron B.M., Cohen H.A. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007, 33:491-495.
-
(2007)
Child Care Health Dev.
, vol.33
, pp. 491-495
-
-
Blau, H.1
Mussaffi, H.2
Zahav, M.M.3
Prais, D.4
Livne, M.5
Czitron, B.M.6
Cohen, H.A.7
-
23
-
-
20144379949
-
Bacterial contamination of spacer devices used by asthmatic children
-
Cohen H.A., Cohen Z., Pomeranz A.S., Czitron B., Kahan E. Bacterial contamination of spacer devices used by asthmatic children. J. Asthma 2005, 42:169-172.
-
(2005)
J. Asthma
, vol.42
, pp. 169-172
-
-
Cohen, H.A.1
Cohen, Z.2
Pomeranz, A.S.3
Czitron, B.4
Kahan, E.5
-
24
-
-
12244290577
-
Bacterial contamination of inhalation chambers: results of a pilot study
-
De Vries T.W., Rienstra S.R., Van Der Vorm E.R. Bacterial contamination of inhalation chambers: results of a pilot study. J. Aerosol Med. 2004, 17:354-356.
-
(2004)
J. Aerosol Med.
, vol.17
, pp. 354-356
-
-
De Vries, T.W.1
Rienstra, S.R.2
Van Der Vorm, E.R.3
-
25
-
-
84858618162
-
Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces
-
Zhou Q., Morton D. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Adv. Drug Deliv. Rev. 2012, 64:275-284.
-
(2012)
Adv. Drug Deliv. Rev.
, vol.64
, pp. 275-284
-
-
Zhou, Q.1
Morton, D.2
-
26
-
-
78650204557
-
Pulmonary formulations: what remains to be done?
-
Weers J.G., Bell J., Chan H.K., Cipolla D., Dunbar C., Hickey A.J., Smith I.J. Pulmonary formulations: what remains to be done?. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl. 2):S5-S23.
-
(2010)
J. Aerosol Med. Pulm. Drug Deliv.
, vol.23
, pp. S5-S23
-
-
Weers, J.G.1
Bell, J.2
Chan, H.K.3
Cipolla, D.4
Dunbar, C.5
Hickey, A.J.6
Smith, I.J.7
-
27
-
-
84873706384
-
The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules
-
Sou T., Kaminskas L.M., Nguyen T.H., Carlberg R., McIntosh M.P., Morton D.A.V. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur. J. Pharm. Biopharm. 2013, 83:234-243.
-
(2013)
Eur. J. Pharm. Biopharm.
, vol.83
, pp. 234-243
-
-
Sou, T.1
Kaminskas, L.M.2
Nguyen, T.H.3
Carlberg, R.4
McIntosh, M.P.5
Morton, D.A.V.6
-
28
-
-
81755166194
-
Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach
-
Sou T., Orlando L., McIntosh M.P., Kaminskas L.M., Morton D.A.V. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int. J. Pharm. 2011, 421:220-229.
-
(2011)
Int. J. Pharm.
, vol.421
, pp. 220-229
-
-
Sou, T.1
Orlando, L.2
McIntosh, M.P.3
Kaminskas, L.M.4
Morton, D.A.V.5
-
29
-
-
84896704931
-
Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery
-
Hoe S., Ivey J.W., Boraey M.A., Shamsaddini-Shahrbabak A., Javaheri E., Matinkhoo S., Finlay W.H., Vehring R. Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm. Res. 2014, 31:449-465.
-
(2014)
Pharm. Res.
, vol.31
, pp. 449-465
-
-
Hoe, S.1
Ivey, J.W.2
Boraey, M.A.3
Shamsaddini-Shahrbabak, A.4
Javaheri, E.5
Matinkhoo, S.6
Finlay, W.H.7
Vehring, R.8
-
30
-
-
61849181513
-
Direct evidence on reduced adhesion of Salbutamol sulphate particles due to L-leucine coating
-
Paajanen M., Katainen J., Raula J., Kauppinen E.I., Lahtinen J. Direct evidence on reduced adhesion of Salbutamol sulphate particles due to L-leucine coating. Powder Technol. 2009, 192:6-11.
-
(2009)
Powder Technol.
, vol.192
, pp. 6-11
-
-
Paajanen, M.1
Katainen, J.2
Raula, J.3
Kauppinen, E.I.4
Lahtinen, J.5
-
31
-
-
72449183575
-
Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders
-
Raula J., Thielmann F., Naderi M., Lehto V.P., Kauppinen E.I. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders. Int. J. Pharm. 2010, 385:79-85.
-
(2010)
Int. J. Pharm.
, vol.385
, pp. 79-85
-
-
Raula, J.1
Thielmann, F.2
Naderi, M.3
Lehto, V.P.4
Kauppinen, E.I.5
-
32
-
-
79961039597
-
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology
-
Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-182.
-
(2011)
J. Aerosol Med. Pulm. Drug Deliv.
, vol.24
, pp. 175-182
-
-
Geller, D.E.1
Weers, J.2
Heuerding, S.3
-
33
-
-
84878695314
-
Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a Phase I study
-
Stass H., Nagelschmitz J., Willmann S., Delesen H., Gupta A., Baumann S. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a Phase I study. Clin. Drug Invest. 2013, 33:419-427.
-
(2013)
Clin. Drug Invest.
, vol.33
, pp. 419-427
-
-
Stass, H.1
Nagelschmitz, J.2
Willmann, S.3
Delesen, H.4
Gupta, A.5
Baumann, S.6
-
34
-
-
84896795789
-
The PulmoSphere™ platform for pulmonary drug delivery
-
Weers J., Tarara T. The PulmoSphere™ platform for pulmonary drug delivery. Ther. Deliv. 2014, 5:277-295.
-
(2014)
Ther. Deliv.
, vol.5
, pp. 277-295
-
-
Weers, J.1
Tarara, T.2
-
35
-
-
79961060764
-
Aerosol performance of tobramycin inhalation powder
-
Haynes A., Nakamura J., Heng C., Heuerding S., Thompson G., Malcolmson R. Aerosol performance of tobramycin inhalation powder. Respir. Drug Deliv. 2010, 701-706.
-
(2010)
Respir. Drug Deliv.
, pp. 701-706
-
-
Haynes, A.1
Nakamura, J.2
Heng, C.3
Heuerding, S.4
Thompson, G.5
Malcolmson, R.6
-
36
-
-
33846068813
-
Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older
-
Tiddens H.A., Geller D.E., Challoner P., Speirs R.J., Kesser K.C., Overbeek S.E., Humble D., Shrewsbury S.B., Standaert T.A. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol Med. 2006, 19:456-465.
-
(2006)
J. Aerosol Med.
, vol.19
, pp. 456-465
-
-
Tiddens, H.A.1
Geller, D.E.2
Challoner, P.3
Speirs, R.J.4
Kesser, K.C.5
Overbeek, S.E.6
Humble, D.7
Shrewsbury, S.B.8
Standaert, T.A.9
-
37
-
-
43349083052
-
Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin
-
Fiegel J., Garcia-Contreras L., Thomas M., VerBerkmoes J., Elbert K., Hickey A., Edwards D. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 2008, 25:805-811.
-
(2008)
Pharm. Res.
, vol.25
, pp. 805-811
-
-
Fiegel, J.1
Garcia-Contreras, L.2
Thomas, M.3
VerBerkmoes, J.4
Elbert, K.5
Hickey, A.6
Edwards, D.7
-
38
-
-
84877855898
-
Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis
-
Dharmadhikari A.S., Kabadi M., Gerety B., Hickey A.J., Fourie P.B., Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 2013, 57:2613-2619.
-
(2013)
Antimicrob. Agents Chemother.
, vol.57
, pp. 2613-2619
-
-
Dharmadhikari, A.S.1
Kabadi, M.2
Gerety, B.3
Hickey, A.J.4
Fourie, P.B.5
Nardell, E.6
-
39
-
-
10744225450
-
Direct lung delivery of para-aminosalicylic acid by aerosol particles
-
Tsapis N., Bennett D., O'Driscoll K., Shea K., Lipp M.M., Fu K., Clarke R.W., Deaver D., Yamins D., Wright J., Peloquin C.A., Weitz D.A., Edwards D.A. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis 2003, 83:379-385.
-
(2003)
Tuberculosis
, vol.83
, pp. 379-385
-
-
Tsapis, N.1
Bennett, D.2
O'Driscoll, K.3
Shea, K.4
Lipp, M.M.5
Fu, K.6
Clarke, R.W.7
Deaver, D.8
Yamins, D.9
Wright, J.10
Peloquin, C.A.11
Weitz, D.A.12
Edwards, D.A.13
-
40
-
-
84864645030
-
Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state
-
Gad S., Tajber L., Corrigan O.I., Healy A.M. Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state. J. Pharm. Pharmacol. 2012, 64:1264-1274.
-
(2012)
J. Pharm. Pharmacol.
, vol.64
, pp. 1264-1274
-
-
Gad, S.1
Tajber, L.2
Corrigan, O.I.3
Healy, A.M.4
-
42
-
-
84898015823
-
A novel inhalable form of rifapentine
-
Chan J.G.Y., Duke C.C., Ong H.X., Chan J.C.Y., Tyne A.S., Chan H.K., Britton W.J., Young P.M., Traini D. A novel inhalable form of rifapentine. J. Pharm. Sci. 2014, 103:1411-1421.
-
(2014)
J. Pharm. Sci.
, vol.103
, pp. 1411-1421
-
-
Chan, J.G.Y.1
Duke, C.C.2
Ong, H.X.3
Chan, J.C.Y.4
Tyne, A.S.5
Chan, H.K.6
Britton, W.J.7
Young, P.M.8
Traini, D.9
-
43
-
-
77953812120
-
Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach
-
Zhou Q.T., Qu L., Larson I., Stewart P.J., Morton D.A.V. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int. J. Pharm. 2010, 394:50-59.
-
(2010)
Int. J. Pharm.
, vol.394
, pp. 50-59
-
-
Zhou, Q.T.1
Qu, L.2
Larson, I.3
Stewart, P.J.4
Morton, D.A.V.5
-
44
-
-
84878600984
-
Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers
-
Zhou Q., Qu L., Gengenbach T., Larson I., Stewart P.J., Morton D.A.V. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS Pharmscitech 2013, 14:38-44.
-
(2013)
AAPS Pharmscitech
, vol.14
, pp. 38-44
-
-
Zhou, Q.1
Qu, L.2
Gengenbach, T.3
Larson, I.4
Stewart, P.J.5
Morton, D.A.V.6
-
45
-
-
79958804877
-
Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach
-
Zhou Q., Denman J.A., Gengenbach T., Das S., Qu L., Zhang H.L., Larson I., Stewart P.J., Morton D.A.V. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J. Pharm. Sci. 2011, 100:3421-3430.
-
(2011)
J. Pharm. Sci.
, vol.100
, pp. 3421-3430
-
-
Zhou, Q.1
Denman, J.A.2
Gengenbach, T.3
Das, S.4
Qu, L.5
Zhang, H.L.6
Larson, I.7
Stewart, P.J.8
Morton, D.A.V.9
-
46
-
-
77953957709
-
Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders
-
Zhou Q.T., Armstrong B., Larson I., Stewart P.J., Morton D. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. Eur. J. Pharm. Sci. 2010, 40:412-421.
-
(2010)
Eur. J. Pharm. Sci.
, vol.40
, pp. 412-421
-
-
Zhou, Q.T.1
Armstrong, B.2
Larson, I.3
Stewart, P.J.4
Morton, D.5
-
47
-
-
63949086375
-
Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency
-
Parlati C., Colombo P., Buttini F., Young P.M., Adi H., Ammit A.J., Traini D. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm. Res. 2009, 26:1084-1092.
-
(2009)
Pharm. Res.
, vol.26
, pp. 1084-1092
-
-
Parlati, C.1
Colombo, P.2
Buttini, F.3
Young, P.M.4
Adi, H.5
Ammit, A.J.6
Traini, D.7
-
48
-
-
84903382795
-
Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction
-
Belotti S., Rossi A., Colombo P., Bettini R., Rekkas D., Politis S., Colombo G., Balducci A.G., Buttini F. Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int. J. Pharm. 2014, 471:507-515.
-
(2014)
Int. J. Pharm.
, vol.471
, pp. 507-515
-
-
Belotti, S.1
Rossi, A.2
Colombo, P.3
Bettini, R.4
Rekkas, D.5
Politis, S.6
Colombo, G.7
Balducci, A.G.8
Buttini, F.9
-
49
-
-
84930088821
-
Inhaled antimicrobial therapy - barriers to effective treatment
-
Weers J. Inhaled antimicrobial therapy - barriers to effective treatment. Adv. Drug Deliv. Rev. 2014, (In press). 10.1016/j.addr.2014.08.013.
-
(2014)
Adv. Drug Deliv. Rev.
-
-
Weers, J.1
-
50
-
-
0037177484
-
A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy
-
Columbano A., Buckton G., Wikeley P. A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy. Int. J. Pharm. 2002, 237:171-178.
-
(2002)
Int. J. Pharm.
, vol.237
, pp. 171-178
-
-
Columbano, A.1
Buckton, G.2
Wikeley, P.3
-
51
-
-
79958852605
-
Characterization and quantification of amorphous material in milled and spray-dried salbutamol sulfate: a comparison of thermal, spectroscopic, and water vapor sorption approaches
-
Grisedale L.C., Jamieson M.J., Belton P.S., Barker S.A., Craig D.Q.M. Characterization and quantification of amorphous material in milled and spray-dried salbutamol sulfate: a comparison of thermal, spectroscopic, and water vapor sorption approaches. J. Pharm. Sci. 2011, 100:3114-3129.
-
(2011)
J. Pharm. Sci.
, vol.100
, pp. 3114-3129
-
-
Grisedale, L.C.1
Jamieson, M.J.2
Belton, P.S.3
Barker, S.A.4
Craig, D.Q.M.5
-
52
-
-
84858798826
-
Isothermal microcalorimetry for quantifying amorphous content in processed pharmaceuticals
-
Gaisford S. Isothermal microcalorimetry for quantifying amorphous content in processed pharmaceuticals. Adv. Drug Deliv. Rev. 2012, 64:431-439.
-
(2012)
Adv. Drug Deliv. Rev.
, vol.64
, pp. 431-439
-
-
Gaisford, S.1
-
53
-
-
77953021975
-
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease
-
Adi H., Young P.M., Chan H.-K., Agus H., Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 2010, 40:239-247.
-
(2010)
Eur. J. Pharm. Sci.
, vol.40
, pp. 239-247
-
-
Adi, H.1
Young, P.M.2
Chan, H.-K.3
Agus, H.4
Traini, D.5
-
54
-
-
84883824014
-
Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation
-
Zhou Q., Morton D., Yu H.H., Jacob J., Wang J.P., Li J., Chan H.K. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. J. Pharm. Sci. 2013, 102:3736-3747.
-
(2013)
J. Pharm. Sci.
, vol.102
, pp. 3736-3747
-
-
Zhou, Q.1
Morton, D.2
Yu, H.H.3
Jacob, J.4
Wang, J.P.5
Li, J.6
Chan, H.K.7
-
55
-
-
84883776964
-
Investigating the particle engineering of colistin for pulmonary delivery
-
Morton D.A.V., Jong T., Li J., Hale J.D., Nation R.L., Larson I. Investigating the particle engineering of colistin for pulmonary delivery. Respiratory Drug Delivery Europe 2011 2011, 367-372.
-
(2011)
Respiratory Drug Delivery Europe 2011
, pp. 367-372
-
-
Morton, D.A.V.1
Jong, T.2
Li, J.3
Hale, J.D.4
Nation, R.L.5
Larson, I.6
-
56
-
-
84893113797
-
Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection
-
Zhou Q., Gengenbach T., Denman J., Yu H., Li J., Chan H. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014, 16:37-47.
-
(2014)
AAPS J.
, vol.16
, pp. 37-47
-
-
Zhou, Q.1
Gengenbach, T.2
Denman, J.3
Yu, H.4
Li, J.5
Chan, H.6
-
57
-
-
33847797216
-
Liposome-based drug delivery to alveolar macrophages
-
Vyas S.P., Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin. Drug Deliv. 2007, 4:95-99.
-
(2007)
Expert Opin. Drug Deliv.
, vol.4
, pp. 95-99
-
-
Vyas, S.P.1
Khatri, K.2
-
58
-
-
80051496632
-
Targeted liposomal drug delivery to monocytes and macrophages
-
727241
-
Kelly C., Jefferies C., Cryan S.-A. Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Deliv. 2011, 727241.
-
(2011)
J. Drug Deliv.
-
-
Kelly, C.1
Jefferies, C.2
Cryan, S.-A.3
-
59
-
-
84930084085
-
Liposomal ciprofloxacin preparation is active against Mycobacterium avium subsp hominissuis and Mycobacterium abscessus in macrophages and in biofilm
-
A6677, San Diego
-
Blanchard J., Danelishvili L., Gonda I., Bermudez L. Liposomal ciprofloxacin preparation is active against Mycobacterium avium subsp hominissuis and Mycobacterium abscessus in macrophages and in biofilm. 2014 American Thoracic Society Conference 2014, A6677, San Diego.
-
(2014)
2014 American Thoracic Society Conference
-
-
Blanchard, J.1
Danelishvili, L.2
Gonda, I.3
Bermudez, L.4
-
60
-
-
74949118665
-
Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages
-
Chono S., Kaneko K., Yamamoto E., Togami K., Morimoto K. Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages. Drug Dev. Ind. Pharm. 2010, 36:102-107.
-
(2010)
Drug Dev. Ind. Pharm.
, vol.36
, pp. 102-107
-
-
Chono, S.1
Kaneko, K.2
Yamamoto, E.3
Togami, K.4
Morimoto, K.5
-
61
-
-
40649093018
-
Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections
-
Chono S., Tanino T., Seki T., Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 2008, 127:50-58.
-
(2008)
J. Control. Release
, vol.127
, pp. 50-58
-
-
Chono, S.1
Tanino, T.2
Seki, T.3
Morimoto, K.4
-
62
-
-
84908226561
-
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans
-
Cipolla D., Shekunov B., Blanchard J., Hickey A. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv. Drug Deliv. Rev. 2014, 75:53-80.
-
(2014)
Adv. Drug Deliv. Rev.
, vol.75
, pp. 53-80
-
-
Cipolla, D.1
Shekunov, B.2
Blanchard, J.3
Hickey, A.4
-
63
-
-
84881542878
-
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
-
Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Goss C.H., Lymp J., Minic P., Quittner A.L., Rubenstein R.C., Young K.R., Saiman L., Burns J.L., Govan J.R.W., Ramsey B., Gupta R., Arikace Study G. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68:818-825.
-
(2013)
Thorax
, vol.68
, pp. 818-825
-
-
Clancy, J.P.1
Dupont, L.2
Konstan, M.W.3
Billings, J.4
Fustik, S.5
Goss, C.H.6
Lymp, J.7
Minic, P.8
Quittner, A.L.9
Rubenstein, R.C.10
Young, K.R.11
Saiman, L.12
Burns, J.L.13
Govan, J.R.W.14
Ramsey, B.15
Gupta, R.16
Arikace Study, G.17
-
64
-
-
54949136128
-
Characterization of nebulized liposomal amikacin (Arikace (TM)) as a function of droplet size
-
Li Z.L., Zhang Y.L., Wurtz W., Lee J.K., Malinin V.S., Durwas-Krishnan S., Meers P., Perkins W.R. Characterization of nebulized liposomal amikacin (Arikace (TM)) as a function of droplet size. J. Aerosol Med. Pulm. Drug Deliv. 2008, 21:245-253.
-
(2008)
J. Aerosol Med. Pulm. Drug Deliv.
, vol.21
, pp. 245-253
-
-
Li, Z.L.1
Zhang, Y.L.2
Wurtz, W.3
Lee, J.K.4
Malinin, V.S.5
Durwas-Krishnan, S.6
Meers, P.7
Perkins, W.R.8
-
65
-
-
70350753018
-
Triggered release of ciprofloxacin from nanostructured agglomerated vesicles
-
Bhavane R., Karathanasis E., Annapragada A.V. Triggered release of ciprofloxacin from nanostructured agglomerated vesicles. Int. J. Nanomedicine 2007, 2:407-418.
-
(2007)
Int. J. Nanomedicine
, vol.2
, pp. 407-418
-
-
Bhavane, R.1
Karathanasis, E.2
Annapragada, A.V.3
-
66
-
-
84901253650
-
Modifying the release properties of liposomes toward personalized medicine
-
Cipolla D., Wu H.Y., Gonda I., Eastman S., Redelmeier T., Chan H.K. Modifying the release properties of liposomes toward personalized medicine. J. Pharm. Sci. 2014, 103:1851-1862.
-
(2014)
J. Pharm. Sci.
, vol.103
, pp. 1851-1862
-
-
Cipolla, D.1
Wu, H.Y.2
Gonda, I.3
Eastman, S.4
Redelmeier, T.5
Chan, H.K.6
-
67
-
-
84881556337
-
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
-
Serisier D.J., Bilton D., De Soyza A., Thompson P.J., Kolbe J., Greville H.W., Cipolla D., Bruinenberg P., Gonda I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
-
(2013)
Thorax
, vol.68
, pp. 812-817
-
-
Serisier, D.J.1
Bilton, D.2
De Soyza, A.3
Thompson, P.J.4
Kolbe, J.5
Greville, H.W.6
Cipolla, D.7
Bruinenberg, P.8
Gonda, I.9
-
68
-
-
78650214408
-
Inhaled liposomal ciprofloxacin: once a day management of respiratory infections
-
Bruinenberg P., Blanchard J., Cipolla D., Dayton F., Mudumba S., Gonda I. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. Respiratory, Drug Delivery 2010, 73-82.
-
(2010)
Respiratory, Drug Delivery
, pp. 73-82
-
-
Bruinenberg, P.1
Blanchard, J.2
Cipolla, D.3
Dayton, F.4
Mudumba, S.5
Gonda, I.6
-
69
-
-
84930090301
-
Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance
-
Cipolla D., Dayton F., Fulzele S., Gabatan E., Mudumba S., Wu H., Yim D., Zwolinski R. Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance. Respiratory Drug Delivery Orlando, FL 2010.
-
(2010)
Respiratory Drug Delivery Orlando, FL
-
-
Cipolla, D.1
Dayton, F.2
Fulzele, S.3
Gabatan, E.4
Mudumba, S.5
Wu, H.6
Yim, D.7
Zwolinski, R.8
-
70
-
-
84881493541
-
Liposomal ciprofloxacin for inhalation retains integrity following nebulization
-
Cipolla D., Wu H., Chan J., Chan H.-K., Gonda I. Liposomal ciprofloxacin for inhalation retains integrity following nebulization. Respiratory Drug Delivery Europe 2013, Berlin, Germany 2013.
-
(2013)
Respiratory Drug Delivery Europe 2013, Berlin, Germany
-
-
Cipolla, D.1
Wu, H.2
Chan, J.3
Chan, H.-K.4
Gonda, I.5
-
71
-
-
84907879111
-
Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties
-
Cipolla D., Wu H., Gonda I., Chan H.-K. Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties. AAPS Pharmscitech 2014, 1-10.
-
(2014)
AAPS Pharmscitech
, pp. 1-10
-
-
Cipolla, D.1
Wu, H.2
Gonda, I.3
Chan, H.-K.4
-
72
-
-
84865304362
-
Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients
-
Elhissi A.M.A., Giebultowicz J., Stec A.A., Wroczynski P., Ahmed W., Alhnan M.A., Phoenix D., Taylor K.M.G. Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients. Int. J. Pharm. 2012, 436:519-526.
-
(2012)
Int. J. Pharm.
, vol.436
, pp. 519-526
-
-
Elhissi, A.M.A.1
Giebultowicz, J.2
Stec, A.A.3
Wroczynski, P.4
Ahmed, W.5
Alhnan, M.A.6
Phoenix, D.7
Taylor, K.M.G.8
-
74
-
-
0036167306
-
A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling
-
Desai T.R., Wong J.P., Hancock R.E., Finlay W.H. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J. Pharm. Sci. 2002, 91:482-491.
-
(2002)
J. Pharm. Sci.
, vol.91
, pp. 482-491
-
-
Desai, T.R.1
Wong, J.P.2
Hancock, R.E.3
Finlay, W.H.4
-
75
-
-
0344083495
-
Delivery of liposomes in dry powder form: aerodynamic dispersion properties
-
Desai T.R., Hancock R.E.W., Finlay W.H. Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur. J. Pharm. Sci. 2003, 20:459-467.
-
(2003)
Eur. J. Pharm. Sci.
, vol.20
, pp. 459-467
-
-
Desai, T.R.1
Hancock, R.E.W.2
Finlay, W.H.3
-
76
-
-
27644447423
-
Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery
-
Sweeney L.G., Wang Z., Loebenberg R., Wong J.P., Lange C.F., Finlay W.H. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 2005, 305:180-185.
-
(2005)
Int. J. Pharm.
, vol.305
, pp. 180-185
-
-
Sweeney, L.G.1
Wang, Z.2
Loebenberg, R.3
Wong, J.P.4
Lange, C.F.5
Finlay, W.H.6
-
77
-
-
84886627480
-
Liposomal antibiotics for the treatment of infectious diseases
-
Alhariri M., Azghani A., Omri A. Liposomal antibiotics for the treatment of infectious diseases. Expert Opin. Drug Deliv. 2013, 10:1515-1532.
-
(2013)
Expert Opin. Drug Deliv.
, vol.10
, pp. 1515-1532
-
-
Alhariri, M.1
Azghani, A.2
Omri, A.3
-
78
-
-
34248199805
-
In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains
-
Gubernator J., Druis-Kawa Z., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains. Lett. Drug Des. Discov. 2007, 4:297-304.
-
(2007)
Lett. Drug Des. Discov.
, vol.4
, pp. 297-304
-
-
Gubernator, J.1
Druis-Kawa, Z.2
Dorotkiewicz-Jach, A.3
Doroszkiewicz, W.4
Kozubek, A.5
-
79
-
-
58249102178
-
The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell
-
Drulis-Kawa Z., Dorotkiewicz-Jach A., Gubernator J., Gula G., Bocer T., Doroszkiewicz W. The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int. J. Pharm. 2009, 367:211-219.
-
(2009)
Int. J. Pharm.
, vol.367
, pp. 211-219
-
-
Drulis-Kawa, Z.1
Dorotkiewicz-Jach, A.2
Gubernator, J.3
Gula, G.4
Bocer, T.5
Doroszkiewicz, W.6
-
80
-
-
12244279936
-
In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate
-
Desai T., Tyrrell G., Ng T., Finlay W. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharm. Res. 2003, 20:442-447.
-
(2003)
Pharm. Res.
, vol.20
, pp. 442-447
-
-
Desai, T.1
Tyrrell, G.2
Ng, T.3
Finlay, W.4
-
81
-
-
84878293341
-
Pharmacology of polymyxins: new insights into an 'old' class of antibiotics
-
Velkov T., Roberts K.D., Nation R.L., Thompson P.E., Li J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 2013, 8:711-724.
-
(2013)
Future Microbiol
, vol.8
, pp. 711-724
-
-
Velkov, T.1
Roberts, K.D.2
Nation, R.L.3
Thompson, P.E.4
Li, J.5
-
82
-
-
84864039471
-
Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation
-
Wallace S.J., Li J., Nation R.L., Prankerd R.J., Boyd B.J. Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. J. Pharm. Sci. 2012, 101:3347-3359.
-
(2012)
J. Pharm. Sci.
, vol.101
, pp. 3347-3359
-
-
Wallace, S.J.1
Li, J.2
Nation, R.L.3
Prankerd, R.J.4
Boyd, B.J.5
-
83
-
-
68349105760
-
Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo
-
Wang D., Kong L., Wang J., He X., Li X., Xiao Y. Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. PDA J. Pharm. Sci. Technol. 2009, 63:159-167.
-
(2009)
PDA J. Pharm. Sci. Technol.
, vol.63
, pp. 159-167
-
-
Wang, D.1
Kong, L.2
Wang, J.3
He, X.4
Li, X.5
Xiao, Y.6
-
84
-
-
84876325172
-
Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies
-
Wallace S.J., Nation R.L., Li J., Boyd B. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J. Pharm. Sci. 2013, 102:1578-1587.
-
(2013)
J. Pharm. Sci.
, vol.102
, pp. 1578-1587
-
-
Wallace, S.J.1
Nation, R.L.2
Li, J.3
Boyd, B.4
-
85
-
-
24044532596
-
Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers
-
Elhissi A.M.A., Taylor K.M.G. Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J. Drug Deliv. Sci. Technol. 2005, 15:261-265.
-
(2005)
J. Drug Deliv. Sci. Technol.
, vol.15
, pp. 261-265
-
-
Elhissi, A.M.A.1
Taylor, K.M.G.2
-
86
-
-
0037038305
-
Preparation and evaluation of proliposomes containing salmon calcitonin
-
Song K.-H., Chung S.-J., Shim C.-K. Preparation and evaluation of proliposomes containing salmon calcitonin. J. Control. Release 2002, 84:27-37.
-
(2002)
J. Control. Release
, vol.84
, pp. 27-37
-
-
Song, K.-H.1
Chung, S.-J.2
Shim, C.-K.3
-
87
-
-
79960774579
-
Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies
-
Rojanarat W., Changsan N., Tawithong E., Pinsuwan S., Chan H.K., Srichana T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int. J. Mol. Sci. 2011, 12:4414-4434.
-
(2011)
Int. J. Mol. Sci.
, vol.12
, pp. 4414-4434
-
-
Rojanarat, W.1
Changsan, N.2
Tawithong, E.3
Pinsuwan, S.4
Chan, H.K.5
Srichana, T.6
-
88
-
-
84895925406
-
Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach
-
Patil-Gadhe A., Pokharkar V. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulm. Pharmacol. Ther. 2014, 27:197-207.
-
(2014)
Pulm. Pharmacol. Ther.
, vol.27
, pp. 197-207
-
-
Patil-Gadhe, A.1
Pokharkar, V.2
-
89
-
-
84866112598
-
Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)
-
Riley T., Christopher D., Arp J., Casazza A., Colombani A., Cooper A., Dey M., Maas J., Mitchell J., Reiners M., Sigari N., Tougas T., Lyapustina S. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS Pharmscitech 2012, 13:978-989.
-
(2012)
AAPS Pharmscitech
, vol.13
, pp. 978-989
-
-
Riley, T.1
Christopher, D.2
Arp, J.3
Casazza, A.4
Colombani, A.5
Cooper, A.6
Dey, M.7
Maas, J.8
Mitchell, J.9
Reiners, M.10
Sigari, N.11
Tougas, T.12
Lyapustina, S.13
-
90
-
-
84890527843
-
Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation
-
Cipolla D., Wu H., Eastman S., Redelmeier T., Gonda I., Chan H.-K. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J. Pharm. Sci. 2014, 103:314-327.
-
(2014)
J. Pharm. Sci.
, vol.103
, pp. 314-327
-
-
Cipolla, D.1
Wu, H.2
Eastman, S.3
Redelmeier, T.4
Gonda, I.5
Chan, H.-K.6
-
91
-
-
84872118822
-
Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia
-
Ong H.X., Traini D., Cipolla D., Gonda I., Bebawy M., Agus H., Young P.M. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res. 2012, 29:3335-3346.
-
(2012)
Pharm. Res.
, vol.29
, pp. 3335-3346
-
-
Ong, H.X.1
Traini, D.2
Cipolla, D.3
Gonda, I.4
Bebawy, M.5
Agus, H.6
Young, P.M.7
-
92
-
-
84881539706
-
Liposomal formulations for inhalation
-
Cipolla D., Gonda I., Chan H.K. Liposomal formulations for inhalation. Ther. Deliv. 2013, 4:1047-1072.
-
(2013)
Ther. Deliv.
, vol.4
, pp. 1047-1072
-
-
Cipolla, D.1
Gonda, I.2
Chan, H.K.3
-
93
-
-
68249124509
-
Preparation and evaluation of controlled release microparticles for respiratory protein therapy
-
Salama R.O., Traini D., Chan H.K., Sung A., Ammit A.J., Young P.M. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J. Pharm. Sci. 2009, 98:2709-2717.
-
(2009)
J. Pharm. Sci.
, vol.98
, pp. 2709-2717
-
-
Salama, R.O.1
Traini, D.2
Chan, H.K.3
Sung, A.4
Ammit, A.J.5
Young, P.M.6
-
94
-
-
84876092106
-
Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles
-
Roberts R.A., Shen T., Allen I.C., Hasan W., DeSimone J.M., Ting J.P.Y. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One 2013, 8:e62115.
-
(2013)
PLoS One
, vol.8
, pp. e62115
-
-
Roberts, R.A.1
Shen, T.2
Allen, I.C.3
Hasan, W.4
DeSimone, J.M.5
Ting, J.P.Y.6
-
95
-
-
33746355591
-
Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung
-
Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M., Kissel T., Seeger W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 2006, 215:100-108.
-
(2006)
Toxicol. Appl. Pharmacol.
, vol.215
, pp. 100-108
-
-
Dailey, L.A.1
Jekel, N.2
Fink, L.3
Gessler, T.4
Schmehl, T.5
Wittmar, M.6
Kissel, T.7
Seeger, W.8
-
96
-
-
0023886553
-
Long term histopathologic follow-up of bronchial arteries after therapeutic embolization with polyvinyl alcohol (Ivalon) in patients with cystic fibrosis
-
Tomashefski J.F., Cohen A.M., Doershuk C.F. Long term histopathologic follow-up of bronchial arteries after therapeutic embolization with polyvinyl alcohol (Ivalon) in patients with cystic fibrosis. Hum. Pathol. 1988, 19:555-561.
-
(1988)
Hum. Pathol.
, vol.19
, pp. 555-561
-
-
Tomashefski, J.F.1
Cohen, A.M.2
Doershuk, C.F.3
-
97
-
-
74949121129
-
Controlled release antibiotics for dry powder lung delivery
-
Adi H., Young P.M., Chan H.K., Salama R., Traini D. Controlled release antibiotics for dry powder lung delivery. Drug Dev. Ind. Pharm. 2010, 36:119-126.
-
(2010)
Drug Dev. Ind. Pharm.
, vol.36
, pp. 119-126
-
-
Adi, H.1
Young, P.M.2
Chan, H.K.3
Salama, R.4
Traini, D.5
-
98
-
-
77955453531
-
Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile
-
Cheow W.S., Chang M.W., Hadinoto K. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm. Res. 2010, 27:1597-1609.
-
(2010)
Pharm. Res.
, vol.27
, pp. 1597-1609
-
-
Cheow, W.S.1
Chang, M.W.2
Hadinoto, K.3
-
99
-
-
80054082800
-
The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics
-
Cheow W.S., Chang M.W., Hadinoto K. The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf. A Physicochem. Eng. Asp. 2011, 389:158-165.
-
(2011)
Colloids Surf. A Physicochem. Eng. Asp.
, vol.389
, pp. 158-165
-
-
Cheow, W.S.1
Chang, M.W.2
Hadinoto, K.3
-
100
-
-
81255137213
-
Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers
-
Ungaro F., d'Angelo I., Coletta C., Bianca R.D.D., Sorrentino R., Perfetto B., Tufano M.A., Miro A., La Rotonda M.I., Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release 2012, 157:149-159.
-
(2012)
J. Control. Release
, vol.157
, pp. 149-159
-
-
Ungaro, F.1
d'Angelo, I.2
Coletta, C.3
Bianca, R.D.D.4
Sorrentino, R.5
Perfetto, B.6
Tufano, M.A.7
Miro, A.8
La Rotonda, M.I.9
Quaglia, F.10
-
101
-
-
84864697452
-
Preparation of sustained release rifampicin microparticles for inhalation
-
Son Y.-J., McConville J.T. Preparation of sustained release rifampicin microparticles for inhalation. J. Pharm. Pharmacol. 2012, 64:1291-1302.
-
(2012)
J. Pharm. Pharmacol.
, vol.64
, pp. 1291-1302
-
-
Son, Y.-J.1
McConville, J.T.2
-
102
-
-
70350324932
-
Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization
-
Doan T.V.P., Olivier J.C. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. Int. J. Pharm. 2009, 382:61-66.
-
(2009)
Int. J. Pharm.
, vol.382
, pp. 61-66
-
-
Doan, T.V.P.1
Olivier, J.C.2
-
103
-
-
55049084615
-
Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles
-
Manca M.L., Loy G., Zaru M., Fadda A.M., Antimisiaris S.G. Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles. Colloids Surf. B: Biointerfaces 2008, 67:166-170.
-
(2008)
Colloids Surf. B: Biointerfaces
, vol.67
, pp. 166-170
-
-
Manca, M.L.1
Loy, G.2
Zaru, M.3
Fadda, A.M.4
Antimisiaris, S.G.5
-
104
-
-
79959750261
-
Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery
-
Doan T.V.P., Couet W., Olivier J.C. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int. J. Pharm. 2011, 414:112-117.
-
(2011)
Int. J. Pharm.
, vol.414
, pp. 112-117
-
-
Doan, T.V.P.1
Couet, W.2
Olivier, J.C.3
-
105
-
-
84865799323
-
Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting
-
Diab R., Brillault J., Bardy A., Gontijo A.V.L., Olivier J.C. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting. Int. J. Pharm. 2012, 436:833-839.
-
(2012)
Int. J. Pharm.
, vol.436
, pp. 833-839
-
-
Diab, R.1
Brillault, J.2
Bardy, A.3
Gontijo, A.V.L.4
Olivier, J.C.5
-
106
-
-
34247639902
-
Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content
-
Budhian A., Siegel S.J., Winey K.I. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int. J. Pharm. 2007, 336:367-375.
-
(2007)
Int. J. Pharm.
, vol.336
, pp. 367-375
-
-
Budhian, A.1
Siegel, S.J.2
Winey, K.I.3
-
107
-
-
47249088124
-
Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique
-
Ito F., Fujimori H., Honnami H., Kawakami H., Kanamura K., Makino K. Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique. Colloids Surf. B: Biointerfaces 2008, 66:65-70.
-
(2008)
Colloids Surf. B: Biointerfaces
, vol.66
, pp. 65-70
-
-
Ito, F.1
Fujimori, H.2
Honnami, H.3
Kawakami, H.4
Kanamura, K.5
Makino, K.6
-
108
-
-
84860576610
-
Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system
-
Hu C., Feng H., Zhu C. Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system. Colloids Surf. B: Biointerfaces 2012, 95:162-169.
-
(2012)
Colloids Surf. B: Biointerfaces
, vol.95
, pp. 162-169
-
-
Hu, C.1
Feng, H.2
Zhu, C.3
-
110
-
-
80053415669
-
Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid
-
Pourshahab P.S., Gilani K., Moazeni E., Eslahi H., Fazeli M.R., Jamalifar H. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J. Microencapsul. 2011, 28:605-613.
-
(2011)
J. Microencapsul.
, vol.28
, pp. 605-613
-
-
Pourshahab, P.S.1
Gilani, K.2
Moazeni, E.3
Eslahi, H.4
Fazeli, M.R.5
Jamalifar, H.6
-
111
-
-
79957692320
-
Formation, characterization, and fate of inhaled drug nanoparticles
-
Zhang J., Wu L., Chan H.-K., Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:441-455.
-
(2011)
Adv. Drug Deliv. Rev.
, vol.63
, pp. 441-455
-
-
Zhang, J.1
Wu, L.2
Chan, H.-K.3
Watanabe, W.4
-
112
-
-
84862776736
-
A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles
-
Wang Y.J., Kho K., Cheow W.S., Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int. J. Pharm. 2012, 424:98-106.
-
(2012)
Int. J. Pharm.
, vol.424
, pp. 98-106
-
-
Wang, Y.J.1
Kho, K.2
Cheow, W.S.3
Hadinoto, K.4
-
113
-
-
80054697360
-
Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former
-
Yamasaki K., Kwok P.C.L., Fukushige K., Prud'homme R.K., Chan H.K. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int. J. Pharm. 2011, 420:34-42.
-
(2011)
Int. J. Pharm.
, vol.420
, pp. 34-42
-
-
Yamasaki, K.1
Kwok, P.C.L.2
Fukushige, K.3
Prud'homme, R.K.4
Chan, H.K.5
-
114
-
-
0037126053
-
Trojan particles: large porous carriers of nanoparticles for drug delivery
-
Tsapis N., Bennett D., Jackson B., Weitz D.A., Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. 2002, 99:12001-12005.
-
(2002)
Proc. Natl. Acad. Sci.
, vol.99
, pp. 12001-12005
-
-
Tsapis, N.1
Bennett, D.2
Jackson, B.3
Weitz, D.A.4
Edwards, D.A.5
-
115
-
-
78650677959
-
Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants
-
Cheow W.S., Ng M.L.L., Kho K., Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int. J. Pharm. 2011, 404:289-300.
-
(2011)
Int. J. Pharm.
, vol.404
, pp. 289-300
-
-
Cheow, W.S.1
Ng, M.L.L.2
Kho, K.3
Hadinoto, K.4
-
116
-
-
84886099200
-
Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying
-
D'Addio S.M., Chan J.G.Y., Kwok P.C.L., Benson B.R., Prud'homme R.K., Chan H.-K. Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying. Pharm. Res. 2013, 30:2891-2901.
-
(2013)
Pharm. Res.
, vol.30
, pp. 2891-2901
-
-
D'Addio, S.M.1
Chan, J.G.Y.2
Kwok, P.C.L.3
Benson, B.R.4
Prud'homme, R.K.5
Chan, H.-K.6
-
117
-
-
84859106992
-
Constant size, variable density aerosol particles by ultrasonic spray freeze drying
-
D'Addio S.M., Chan J.G.Y., Kwok P.C.L., Prud'homme R.K., Chan H.-K. Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int. J. Pharm. 2012, 427:185-191.
-
(2012)
Int. J. Pharm.
, vol.427
, pp. 185-191
-
-
D'Addio, S.M.1
Chan, J.G.Y.2
Kwok, P.C.L.3
Prud'homme, R.K.4
Chan, H.-K.5
-
118
-
-
77951630453
-
Development and optimization of solid lipid nanoparticles of amikacin by central composite design
-
Varshosaz J., Ghaffari S., Khoshayand M.R., Atyabi F., Azarmi S., Kobarfard F. Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J. Liposome Res. 2010, 20:97-104.
-
(2010)
J. Liposome Res.
, vol.20
, pp. 97-104
-
-
Varshosaz, J.1
Ghaffari, S.2
Khoshayand, M.R.3
Atyabi, F.4
Azarmi, S.5
Kobarfard, F.6
-
119
-
-
84857423152
-
Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design
-
Varshosaz J., Ghaffari S., Khoshayand M.R., Atyabi F., Dehkordi A.J., Kobarfard F. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. Pharm. Dev. Technol. 2012, 17:187-194.
-
(2012)
Pharm. Dev. Technol.
, vol.17
, pp. 187-194
-
-
Varshosaz, J.1
Ghaffari, S.2
Khoshayand, M.R.3
Atyabi, F.4
Dehkordi, A.J.5
Kobarfard, F.6
-
120
-
-
79251488476
-
Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles
-
Ghaffari S., Varshosaz J., Saadat A., Atyabi F. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. Int. J. Nanomedicine 2010, 6:35-43.
-
(2010)
Int. J. Nanomedicine
, vol.6
, pp. 35-43
-
-
Ghaffari, S.1
Varshosaz, J.2
Saadat, A.3
Atyabi, F.4
-
121
-
-
77958098366
-
Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols
-
El-Gendy N., Desai V., Berkland C. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J. Pharm. Innov. 2010, 5:79-87.
-
(2010)
J. Pharm. Innov.
, vol.5
, pp. 79-87
-
-
El-Gendy, N.1
Desai, V.2
Berkland, C.3
-
122
-
-
57049159889
-
Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery
-
Pilcer G., Vanderbist F., Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int. J. Pharm. 2009, 365:162-169.
-
(2009)
Int. J. Pharm.
, vol.365
, pp. 162-169
-
-
Pilcer, G.1
Vanderbist, F.2
Amighi, K.3
-
124
-
-
84864040393
-
Development of budesonide nanocluster dry powder aerosols: processing
-
El-Gendy N., Selvam P., Soni P., Berkland C. Development of budesonide nanocluster dry powder aerosols: processing. J. Pharm. Sci. 2012, 101:3425-3433.
-
(2012)
J. Pharm. Sci.
, vol.101
, pp. 3425-3433
-
-
El-Gendy, N.1
Selvam, P.2
Soni, P.3
Berkland, C.4
-
125
-
-
84899430751
-
Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product
-
Backman P., Adelmann H., Petersson G., Jones C.B. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin. Pharmacol. Ther. 2014, 95:509-520.
-
(2014)
Clin. Pharmacol. Ther.
, vol.95
, pp. 509-520
-
-
Backman, P.1
Adelmann, H.2
Petersson, G.3
Jones, C.B.4
-
127
-
-
33748697027
-
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii
-
Li J., Rayner C.R., Nation R.L., Owen R.J., Spelman D., Tan K.E., Liojios L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2006, 50:2946-2950.
-
(2006)
Antimicrob. Agents Chemother.
, vol.50
, pp. 2946-2950
-
-
Li, J.1
Rayner, C.R.2
Nation, R.L.3
Owen, R.J.4
Spelman, D.5
Tan, K.E.6
Liojios, L.7
-
129
-
-
52449086630
-
Cospray dried antibiotics for dry powder lung delivery
-
Adi H., Young P.M., Chan H.-K., Stewart P., Agus H., Traini D. Cospray dried antibiotics for dry powder lung delivery. J. Pharm. Sci. 2008, 97:3356-3366.
-
(2008)
J. Pharm. Sci.
, vol.97
, pp. 3356-3366
-
-
Adi, H.1
Young, P.M.2
Chan, H.-K.3
Stewart, P.4
Agus, H.5
Traini, D.6
-
130
-
-
33645396484
-
Functional classification of drugs by properties of their pairwise interactions
-
Yeh P., Tschumi A.I., Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 2006, 38:489-494.
-
(2006)
Nat. Genet.
, vol.38
, pp. 489-494
-
-
Yeh, P.1
Tschumi, A.I.2
Kishony, R.3
-
131
-
-
70349444999
-
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
-
MacLeod D.L., Barker L.M., Sutherland J.L., Moss S.C., Gurgel J.L., Kenney T.F., Burns J.L., Baker W.R. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 2009, 64:829-836.
-
(2009)
J. Antimicrob. Chemother.
, vol.64
, pp. 829-836
-
-
MacLeod, D.L.1
Barker, L.M.2
Sutherland, J.L.3
Moss, S.C.4
Gurgel, J.L.5
Kenney, T.F.6
Burns, J.L.7
Baker, W.R.8
-
132
-
-
84857186407
-
Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa
-
MacLeod D.L., Velayudhan J., Kenney T.F., Therrien J.H., Sutherland J.L., Barker L.M., Baker W.R. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2012, 56:1529-1538.
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 1529-1538
-
-
MacLeod, D.L.1
Velayudhan, J.2
Kenney, T.F.3
Therrien, J.H.4
Sutherland, J.L.5
Barker, L.M.6
Baker, W.R.7
-
133
-
-
67651218977
-
Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa
-
Tre-Hardy M., Traore H., El Manssouri N., Vanderbist F., Vaneechoutte M., Devleeschouwer M.J. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 2009, 34:370-374.
-
(2009)
Int. J. Antimicrob. Agents
, vol.34
, pp. 370-374
-
-
Tre-Hardy, M.1
Traore, H.2
El Manssouri, N.3
Vanderbist, F.4
Vaneechoutte, M.5
Devleeschouwer, M.J.6
-
134
-
-
77957358644
-
Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model
-
Tre-Hardy M., Nagant C., El Manssouri N., Vanderbist F., Traore H., Vaneechoutte M., Dehaye J.-P. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob. Agents Chemother. 2010, 54:4409-4415.
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 4409-4415
-
-
Tre-Hardy, M.1
Nagant, C.2
El Manssouri, N.3
Vanderbist, F.4
Traore, H.5
Vaneechoutte, M.6
Dehaye, J.-P.7
-
135
-
-
78349232036
-
Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
-
Herrmann G., Yang L., Wu H., Song Z., Wang H., Hoiby N., Ulrich M., Molin S., Riethmueller J., Doering G. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J. Infect. Dis. 2010, 202:1585-1592.
-
(2010)
J. Infect. Dis.
, vol.202
, pp. 1585-1592
-
-
Herrmann, G.1
Yang, L.2
Wu, H.3
Song, Z.4
Wang, H.5
Hoiby, N.6
Ulrich, M.7
Molin, S.8
Riethmueller, J.9
Doering, G.10
-
136
-
-
84855255192
-
Fosfomycin/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa
-
McColley S.A., Trapnell B., Kissner D., McKevitt M., Montgomery B., Rosen J. Fosfomycin/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa. Pediatr. Pulmonol. 2010, 338-338.
-
(2010)
Pediatr. Pulmonol.
, pp. 338-338
-
-
McColley, S.A.1
Trapnell, B.2
Kissner, D.3
McKevitt, M.4
Montgomery, B.5
Rosen, J.6
-
137
-
-
84873722026
-
Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation
-
Lee S.H., Teo J., Heng D., Ng W.K., Chan H.-K., Tan R.B.H. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation. Eur. J. Pharm. Biopharm. 2013, 83:275-284.
-
(2013)
Eur. J. Pharm. Biopharm.
, vol.83
, pp. 275-284
-
-
Lee, S.H.1
Teo, J.2
Heng, D.3
Ng, W.K.4
Chan, H.-K.5
Tan, R.B.H.6
-
138
-
-
75449151225
-
Ineffectiveness of lysozyme therapy in experimental syphilis in the rabbit
-
Cannefax G.R., Hanson A.W. Ineffectiveness of lysozyme therapy in experimental syphilis in the rabbit. Br. J. Venereal Dis. 1963, 39:192-194.
-
(1963)
Br. J. Venereal Dis.
, vol.39
, pp. 192-194
-
-
Cannefax, G.R.1
Hanson, A.W.2
-
139
-
-
53849117442
-
Microparticles for inhalational delivery of antipseudomonal antibiotics
-
Tsifansky M.D., Yeo Y., Evgenov O.V., Bellas E., Benjamin J., Kohane D.S. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J. 2008, 10:254-260.
-
(2008)
AAPS J.
, vol.10
, pp. 254-260
-
-
Tsifansky, M.D.1
Yeo, Y.2
Evgenov, O.V.3
Bellas, E.4
Benjamin, J.5
Kohane, D.S.6
-
140
-
-
84878571643
-
Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis
-
Pilcer G., De Bueger V., Traina K., Traore H., Sebti T., Vanderbist F., Amighi K. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int. J. Pharm. 2013, 451:112-120.
-
(2013)
Int. J. Pharm.
, vol.451
, pp. 112-120
-
-
Pilcer, G.1
De Bueger, V.2
Traina, K.3
Traore, H.4
Sebti, T.5
Vanderbist, F.6
Amighi, K.7
-
141
-
-
84930088889
-
Formulation and evaluation of dry powders containing anti tuberculosis drugs for pulmonary delivery
-
Gowda D.V., Datta V., Meenakshi S., Gupta V.K. Formulation and evaluation of dry powders containing anti tuberculosis drugs for pulmonary delivery. Indo Am. J. Pharm. Res. 2013, 3:1239-1248.
-
(2013)
Indo Am. J. Pharm. Res.
, vol.3
, pp. 1239-1248
-
-
Gowda, D.V.1
Datta, V.2
Meenakshi, S.3
Gupta, V.K.4
-
142
-
-
34548009339
-
Inhalable microparticles containing large payload of anti-tuberculosis drugs
-
Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 2007, 32:140-150.
-
(2007)
Eur. J. Pharm. Sci.
, vol.32
, pp. 140-150
-
-
Muttil, P.1
Kaur, J.2
Kumar, K.3
Yadav, A.B.4
Sharma, R.5
Misra, A.6
-
143
-
-
84873733393
-
In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid
-
Booysen L.L.I.J., Kalombo L., Brooks E., Hansen R., Gilliland J., Gruppo V., Lungenhofer P., Semete-Makokotlela B., Swai H.S., Kotze A.F., Lenaerts A., du Plessis L.H. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid. Int. J. Pharm. 2013, 444:10-17.
-
(2013)
Int. J. Pharm.
, vol.444
, pp. 10-17
-
-
Booysen, L.L.I.J.1
Kalombo, L.2
Brooks, E.3
Hansen, R.4
Gilliland, J.5
Gruppo, V.6
Lungenhofer, P.7
Semete-Makokotlela, B.8
Swai, H.S.9
Kotze, A.F.10
Lenaerts, A.11
du Plessis, L.H.12
-
144
-
-
84873703779
-
A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics
-
Chan J.G.Y., Chan H.-K., Prestidge C.A., Denman J.A., Young P.M., Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur. J. Pharm. Biopharm. 2013, 83:285-292.
-
(2013)
Eur. J. Pharm. Biopharm.
, vol.83
, pp. 285-292
-
-
Chan, J.G.Y.1
Chan, H.-K.2
Prestidge, C.A.3
Denman, J.A.4
Young, P.M.5
Traini, D.6
-
145
-
-
0034781469
-
Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis
-
Sharma R., Saxena D., Dwivedi A., Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 2001, 18:1405-1410.
-
(2001)
Pharm. Res.
, vol.18
, pp. 1405-1410
-
-
Sharma, R.1
Saxena, D.2
Dwivedi, A.3
Misra, A.4
-
146
-
-
0025888898
-
Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children
-
Seifart H.I., Parkin D.P., Donald P.R. Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children. Pediatr. Infect. Dis. J. 1991, 10:827-831.
-
(1991)
Pediatr. Infect. Dis. J.
, vol.10
, pp. 827-831
-
-
Seifart, H.I.1
Parkin, D.P.2
Donald, P.R.3
-
147
-
-
49049116192
-
The role of chelators in preventing biofilm formation and catheter-related bloodstream infections
-
Raad I.I., Fang X., Keutgen X.M., Jiang Y., Sherertz R., Hachem R. The role of chelators in preventing biofilm formation and catheter-related bloodstream infections. Curr. Opin. Infect. Dis. 2008, 21:385-392.
-
(2008)
Curr. Opin. Infect. Dis.
, vol.21
, pp. 385-392
-
-
Raad, I.I.1
Fang, X.2
Keutgen, X.M.3
Jiang, Y.4
Sherertz, R.5
Hachem, R.6
-
148
-
-
84872731672
-
Antibiotic-EDTA combination induced dispersal of Pseudomonas aeruginosa biofilm
-
Shaikh A.I., Musaddiq M. Antibiotic-EDTA combination induced dispersal of Pseudomonas aeruginosa biofilm. J. Pure Appl. Microbiol. 2012, 6:363-367.
-
(2012)
J. Pure Appl. Microbiol.
, vol.6
, pp. 363-367
-
-
Shaikh, A.I.1
Musaddiq, M.2
-
149
-
-
0037198693
-
A component of innate immunity prevents bacterial biofilm development
-
Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 2002, 417:552-555.
-
(2002)
Nature
, vol.417
, pp. 552-555
-
-
Singh, P.K.1
Parsek, M.R.2
Greenberg, E.P.3
Welsh, M.J.4
-
150
-
-
79952953111
-
Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model
-
Yang Y., Tsifansky M.D., Shin S., Lin Q., Yeo Y. Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol. Bioeng. 2011, 108:1441-1449.
-
(2011)
Biotechnol. Bioeng.
, vol.108
, pp. 1441-1449
-
-
Yang, Y.1
Tsifansky, M.D.2
Shin, S.3
Lin, Q.4
Yeo, Y.5
-
151
-
-
84877093743
-
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
-
Wilson R., Welte T., Polverino E., De Soyza A., Greville H., O'Donnell A., Alder J., Reimnitz P., Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur. Respir. J. 2013, 41:1107-1115.
-
(2013)
Eur. Respir. J.
, vol.41
, pp. 1107-1115
-
-
Wilson, R.1
Welte, T.2
Polverino, E.3
De Soyza, A.4
Greville, H.5
O'Donnell, A.6
Alder, J.7
Reimnitz, P.8
Hampel, B.9
-
152
-
-
79955886933
-
Metabolite-enabled eradication of bacterial persisters by aminoglycosides
-
Allison K.R., Brynildsen M.P., Collins J.J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011, 473:216-220.
-
(2011)
Nature
, vol.473
, pp. 216-220
-
-
Allison, K.R.1
Brynildsen, M.P.2
Collins, J.J.3
-
153
-
-
84892500332
-
Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms
-
Barraud N., Buson A., Jarolimek W., Rice S.A. Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms. PLoS One 2013, 8.
-
(2013)
PLoS One
, vol.8
-
-
Barraud, N.1
Buson, A.2
Jarolimek, W.3
Rice, S.A.4
-
154
-
-
84858234304
-
Long-term inhaled dry powder mannitol in cystic fibrosis an international randomized study
-
Aitken M.L., Bellon G., De Boeck K., Flume P.A., Fox H.G., Geller D.E., Haarman E.G., Hebestreit H.U., Lapey A., Schou I.M., Zuckerman J.B., Charlton B., Investigators C.F. Long-term inhaled dry powder mannitol in cystic fibrosis an international randomized study. Am. J. Respir. Crit. Care Med. 2012, 185:645-652.
-
(2012)
Am. J. Respir. Crit. Care Med.
, vol.185
, pp. 645-652
-
-
Aitken, M.L.1
Bellon, G.2
De Boeck, K.3
Flume, P.A.4
Fox, H.G.5
Geller, D.E.6
Haarman, E.G.7
Hebestreit, H.U.8
Lapey, A.9
Schou, I.M.10
Zuckerman, J.B.11
Charlton, B.12
Investigators, C.F.13
-
155
-
-
84880078608
-
Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis
-
Bilton D., Daviskas E., Anderson S.D., Kolbe J., King G., Stirling R.G., Thompson B.R., Milne D., Charlton B., Investigators B. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013, 144:215-225.
-
(2013)
Chest
, vol.144
, pp. 215-225
-
-
Bilton, D.1
Daviskas, E.2
Anderson, S.D.3
Kolbe, J.4
King, G.5
Stirling, R.G.6
Thompson, B.R.7
Milne, D.8
Charlton, B.9
Investigators, B.10
-
156
-
-
72949104558
-
Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis
-
Yang Y., Tsifansky M.D., Wu C.J., Yang H.I., Schmidt G., Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm. Res. 2010, 27:151-160.
-
(2010)
Pharm. Res.
, vol.27
, pp. 151-160
-
-
Yang, Y.1
Tsifansky, M.D.2
Wu, C.J.3
Yang, H.I.4
Schmidt, G.5
Yeo, Y.6
-
157
-
-
84896360592
-
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy
-
Lee S.H., Teo J., Heng D., Zhao Y., Ng W.K., Chan H.-K., Tan R.B.H. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy. J. Pharm. Sci. 2014, 103:1115-1125.
-
(2014)
J. Pharm. Sci.
, vol.103
, pp. 1115-1125
-
-
Lee, S.H.1
Teo, J.2
Heng, D.3
Zhao, Y.4
Ng, W.K.5
Chan, H.-K.6
Tan, R.B.H.7
-
158
-
-
33750479893
-
Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa
-
Barraud N., Hassett D.J., Hwang S.H., Rice S.A., Kjelleberg S., Webb J.S. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J. Bacteriol. 2006, 188:7344-7353.
-
(2006)
J. Bacteriol.
, vol.188
, pp. 7344-7353
-
-
Barraud, N.1
Hassett, D.J.2
Hwang, S.H.3
Rice, S.A.4
Kjelleberg, S.5
Webb, J.S.6
-
159
-
-
72249092095
-
Nitric oxide signaling in pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic Di-GMP levels, and enhanced dispersal
-
Barraud N., Schleheck D., Klebensberger J., Webb J.S., Hassett D.J., Rice S.A., Kjelleberg S. Nitric oxide signaling in pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic Di-GMP levels, and enhanced dispersal. J. Bacteriol. 2009, 191:7333-7342.
-
(2009)
J. Bacteriol.
, vol.191
, pp. 7333-7342
-
-
Barraud, N.1
Schleheck, D.2
Klebensberger, J.3
Webb, J.S.4
Hassett, D.J.5
Rice, S.A.6
Kjelleberg, S.7
-
160
-
-
72249093590
-
Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms
-
Barraud N., Storey M.V., Moore Z.P., Webb J.S., Rice S.A., Kjelleberg S. Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. Microb. Biotechnol. 2009, 2:370-378.
-
(2009)
Microb. Biotechnol.
, vol.2
, pp. 370-378
-
-
Barraud, N.1
Storey, M.V.2
Moore, Z.P.3
Webb, J.S.4
Rice, S.A.5
Kjelleberg, S.6
-
161
-
-
77951865142
-
D-amino acids trigger biofilm disassembly
-
Kolodkin-Gal I., Romero D., Cao S.G., Clardy J., Kolter R., Losick R. D-amino acids trigger biofilm disassembly. Science 2010, 328:627-629.
-
(2010)
Science
, vol.328
, pp. 627-629
-
-
Kolodkin-Gal, I.1
Romero, D.2
Cao, S.G.3
Clardy, J.4
Kolter, R.5
Losick, R.6
-
162
-
-
80052692215
-
Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens
-
Burrowes B., Harper D.R., Anderson J., McConville M., Enright M.C. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev. Anti-Infect. Ther. 2011, 9:775-785.
-
(2011)
Expert Rev. Anti-Infect. Ther.
, vol.9
, pp. 775-785
-
-
Burrowes, B.1
Harper, D.R.2
Anderson, J.3
McConville, M.4
Enright, M.C.5
-
163
-
-
60649119122
-
Preventing biofilms of clinically relevant organisms using bacteriophage
-
Donlan R.M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 2009, 17:66-72.
-
(2009)
Trends Microbiol.
, vol.17
, pp. 66-72
-
-
Donlan, R.M.1
-
164
-
-
1542321189
-
The interaction of phage and biofilms
-
Sutherland I.W., Hughes K.A., Skillman L.C., Tait K. The interaction of phage and biofilms. FEMS Microbiol. Lett. 2004, 232:1-6.
-
(2004)
FEMS Microbiol. Lett.
, vol.232
, pp. 1-6
-
-
Sutherland, I.W.1
Hughes, K.A.2
Skillman, L.C.3
Tait, K.4
-
165
-
-
34547448587
-
Dispersing biofilms with engineered enzymatic bacteriophage
-
Lu T.K., Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11197-11202.
-
(2007)
Proc. Natl. Acad. Sci. U. S. A.
, vol.104
, pp. 11197-11202
-
-
Lu, T.K.1
Collins, J.J.2
-
166
-
-
84992305842
-
Formulation challenges: protein powders for inhalation
-
Informa Healthcare, New York, M. Rathbone, J. Hadgraft, M. Roberts (Eds.)
-
Chan H.-K. Formulation challenges: protein powders for inhalation. Modified-release Drug Delivery Technology 2008, 631-643. Informa Healthcare, New York. M. Rathbone, J. Hadgraft, M. Roberts (Eds.).
-
(2008)
Modified-release Drug Delivery Technology
, pp. 631-643
-
-
Chan, H.-K.1
-
167
-
-
0001848965
-
The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example
-
Interpharm Press, Buffalo Grove, IL, R. Dalby, P. Byron, S. Farr (Eds.)
-
Clark A., Dasovich N., Gonda I., Chan H.-K. The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example. Respiratory Drug Delivery V 1996, 167-174. Interpharm Press, Buffalo Grove, IL. R. Dalby, P. Byron, S. Farr (Eds.).
-
(1996)
Respiratory Drug Delivery V
, pp. 167-174
-
-
Clark, A.1
Dasovich, N.2
Gonda, I.3
Chan, H.-K.4
-
168
-
-
84882499572
-
Pulmonary delivery of peptides and proteins
-
Academic Press, London, C. Walle (Ed.)
-
Kwok P., Chan H.-K. Pulmonary delivery of peptides and proteins. Peptide and Protein Delivery 2011, 23-46. Academic Press, London. C. Walle (Ed.).
-
(2011)
Peptide and Protein Delivery
, pp. 23-46
-
-
Kwok, P.1
Chan, H.-K.2
-
169
-
-
84886146327
-
Proteins, peptides, and controlled-release formulations for inhalation
-
John Wiley & Sons, P. Colombo, D. Traini, F. Buttini (Eds.)
-
Kwok P., Salama R., Chan H.-K. Proteins, peptides, and controlled-release formulations for inhalation. Inhalation Drug Delivery: Techniques and Products 2012, 121-144. John Wiley & Sons. P. Colombo, D. Traini, F. Buttini (Eds.).
-
(2012)
Inhalation Drug Delivery: Techniques and Products
, pp. 121-144
-
-
Kwok, P.1
Salama, R.2
Chan, H.-K.3
-
170
-
-
0031008878
-
Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery
-
Chan H.K., Clark A., Gonda I., Mumenthaler M., Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 1997, 14:431-437.
-
(1997)
Pharm. Res.
, vol.14
, pp. 431-437
-
-
Chan, H.K.1
Clark, A.2
Gonda, I.3
Mumenthaler, M.4
Hsu, C.5
-
171
-
-
0031596775
-
Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase)
-
Chan H.K., Gonda I. Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase). J. Pharm. Sci. 1998, 87:647-654.
-
(1998)
J. Pharm. Sci.
, vol.87
, pp. 647-654
-
-
Chan, H.K.1
Gonda, I.2
-
172
-
-
0032425197
-
A solid-state NMR study of protein hydration and stability
-
Separovic F., Lam Y.H., Ke X., Chan H.K. A solid-state NMR study of protein hydration and stability. Pharm. Res. 1998, 15:1816-1821.
-
(1998)
Pharm. Res.
, vol.15
, pp. 1816-1821
-
-
Separovic, F.1
Lam, Y.H.2
Ke, X.3
Chan, H.K.4
-
173
-
-
0036279490
-
A solid-state NMR study of protein mobility in lyophilized protein-sugar powders
-
Lam Y.H., Bustami R., Phan T., Chan H.K., Separovic F. A solid-state NMR study of protein mobility in lyophilized protein-sugar powders. J. Pharm. Sci. 2002, 91:943-951.
-
(2002)
J. Pharm. Sci.
, vol.91
, pp. 943-951
-
-
Lam, Y.H.1
Bustami, R.2
Phan, T.3
Chan, H.K.4
Separovic, F.5
-
174
-
-
0012074293
-
A case study in aerosol protein drug development: aqueous solution aerosols of rhDNase
-
Interpharm Press, Buffalo Grove, IL, P. Byron, R. Dalby, S. Farr (Eds.)
-
Gonda I., Cipolla D., Shire S., Meserve K., Weck S., Clark A., Chan H.-K. A case study in aerosol protein drug development: aqueous solution aerosols of rhDNase. Respiratory Drug Delivery IV 1994, 47-54. Interpharm Press, Buffalo Grove, IL. P. Byron, R. Dalby, S. Farr (Eds.).
-
(1994)
Respiratory Drug Delivery IV
, pp. 47-54
-
-
Gonda, I.1
Cipolla, D.2
Shire, S.3
Meserve, K.4
Weck, S.5
Clark, A.6
Chan, H.-K.7
-
175
-
-
0034495097
-
Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide
-
Bustami R.T., Chan H.K., Dehghani F., Foster N.R. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. 2000, 17:1360-1366.
-
(2000)
Pharm. Res.
, vol.17
, pp. 1360-1366
-
-
Bustami, R.T.1
Chan, H.K.2
Dehghani, F.3
Foster, N.R.4
-
176
-
-
0036367565
-
Aerosolization of protein solutions using thermal inkjet technology
-
Goodall S., Chew N., Chan K., Auriac D., Waters M.J. Aerosolization of protein solutions using thermal inkjet technology. J. Aerosol Med. 2002, 15:351-357.
-
(2002)
J. Aerosol Med.
, vol.15
, pp. 351-357
-
-
Goodall, S.1
Chew, N.2
Chan, K.3
Auriac, D.4
Waters, M.J.5
-
177
-
-
68249124509
-
Preparation and evaluation of controlled release microparticles for respiratory protein therapy
-
Salama R.O., Traini D., Chan H.K., Sung A., Ammit A.J., Young P.M. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J. Pharm. Sci. 2009, 98:2709-2717.
-
(2009)
J. Pharm. Sci.
, vol.98
, pp. 2709-2717
-
-
Salama, R.O.1
Traini, D.2
Chan, H.K.3
Sung, A.4
Ammit, A.J.5
Young, P.M.6
-
178
-
-
78650179651
-
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy
-
Lee S.H., Heng D., Ng W.K., Chan H.K., Tan R.B.H. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int. J. Pharm. 2011, 403:192-200.
-
(2011)
Int. J. Pharm.
, vol.403
, pp. 192-200
-
-
Lee, S.H.1
Heng, D.2
Ng, W.K.3
Chan, H.K.4
Tan, R.B.H.5
-
179
-
-
79955603054
-
Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery
-
Kwok P.C.L., Tunsirikongkon A., Glover W., Chan H.K. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm. Res. 2011, 28:788-796.
-
(2011)
Pharm. Res.
, vol.28
, pp. 788-796
-
-
Kwok, P.C.L.1
Tunsirikongkon, A.2
Glover, W.3
Chan, H.K.4
-
180
-
-
84882896414
-
TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines
-
Tyne A.S., Chan J.G.Y., Shanahan E.R., Atmosukarto I., Chan H.-K., Britton W.J., West N.P. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine 2013, 31:4322-4329.
-
(2013)
Vaccine
, vol.31
, pp. 4322-4329
-
-
Tyne, A.S.1
Chan, J.G.Y.2
Shanahan, E.R.3
Atmosukarto, I.4
Chan, H.-K.5
Britton, W.J.6
West, N.P.7
-
181
-
-
80054935550
-
Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections
-
Matinkhoo S., Lynch K.H., Dennis J.J., Finlay W.H., Vehring R. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 2011, 100:5197-5205.
-
(2011)
J. Pharm. Sci.
, vol.100
, pp. 5197-5205
-
-
Matinkhoo, S.1
Lynch, K.H.2
Dennis, J.J.3
Finlay, W.H.4
Vehring, R.5
-
182
-
-
78650125693
-
In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis
-
Golshahi L., Lynch K.H., Dennis J.J., Finlay W.H. In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 2011, 110:106-117.
-
(2011)
J. Appl. Microbiol.
, vol.110
, pp. 106-117
-
-
Golshahi, L.1
Lynch, K.H.2
Dennis, J.J.3
Finlay, W.H.4
-
184
-
-
0034078730
-
Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial
-
Hedrick J.A., Barzilai A., Behre U., Henderson F.W., Hammond J., Reilly L., Keene O. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 2000, 19:410-417.
-
(2000)
Pediatr. Infect. Dis. J.
, vol.19
, pp. 410-417
-
-
Hedrick, J.A.1
Barzilai, A.2
Behre, U.3
Henderson, F.W.4
Hammond, J.5
Reilly, L.6
Keene, O.7
-
185
-
-
62849094735
-
Cascade impactor practice for a high dose dry powder inhaler at 90L/min: NGI versus modified 6-stage and 8-stage ACI
-
Kamiya A., Sakagami M., Byron P.R. Cascade impactor practice for a high dose dry powder inhaler at 90L/min: NGI versus modified 6-stage and 8-stage ACI. J. Pharm. Sci. 2009, 98:1028-1039.
-
(2009)
J. Pharm. Sci.
, vol.98
, pp. 1028-1039
-
-
Kamiya, A.1
Sakagami, M.2
Byron, P.R.3
-
186
-
-
84878413637
-
In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults
-
Delvadia R., Hindle M., Worth Longest P., Byron P.R. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J. Aerosol Med. 2013, 26:138-144.
-
(2013)
J. Aerosol Med.
, vol.26
, pp. 138-144
-
-
Delvadia, R.1
Hindle, M.2
Worth Longest, P.3
Byron, P.R.4
-
187
-
-
0037203724
-
Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM
-
Bérard V., Lesniewska E., Andrès C., Pertuy D., Laroche C., Pourcelot Y. Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM. Int. J. Pharm. 2002, 232:213-224.
-
(2002)
Int. J. Pharm.
, vol.232
, pp. 213-224
-
-
Bérard, V.1
Lesniewska, E.2
Andrès, C.3
Pertuy, D.4
Laroche, C.5
Pourcelot, Y.6
-
188
-
-
84871361554
-
Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics
-
Sunagawa S., Higa F., Cash H.L., Tateyama M., Uno T., Fujita J. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respi. Viruses 2013, 7:1-3.
-
(2013)
Influenza Other Respi. Viruses
, vol.7
, pp. 1-3
-
-
Sunagawa, S.1
Higa, F.2
Cash, H.L.3
Tateyama, M.4
Uno, T.5
Fujita, J.6
-
189
-
-
0035835924
-
Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial
-
Diggory P., Fernandez C., Humphrey A., Jones V., Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001, 322:577-579.
-
(2001)
BMJ
, vol.322
, pp. 577-579
-
-
Diggory, P.1
Fernandez, C.2
Humphrey, A.3
Jones, V.4
Murphy, M.5
-
191
-
-
77953753826
-
Fatal respiratory events caused by zanamivir nebulization
-
Steel H.M., Peppercorn A.F. Fatal respiratory events caused by zanamivir nebulization. Clin. Infect. Dis. 2010, 51:121.
-
(2010)
Clin. Infect. Dis.
, vol.51
, pp. 121
-
-
Steel, H.M.1
Peppercorn, A.F.2
-
192
-
-
0042656406
-
Safety and efficacy of nebulised zanamivir in hospitalized patients with serious influenza
-
Ison M.G., Gnann J.W., Nagy-Agren S., Treannor J., Pava C., Steigbigel R., Elliott M., Weiss H.L., Hayden F.G., N.C.A.S.Group Safety and efficacy of nebulised zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 2003, 8:183-190.
-
(2003)
Antivir. Ther.
, vol.8
, pp. 183-190
-
-
Ison, M.G.1
Gnann, J.W.2
Nagy-Agren, S.3
Treannor, J.4
Pava, C.5
Steigbigel, R.6
Elliott, M.7
Weiss, H.L.8
Hayden, F.G.9
-
193
-
-
84871361554
-
Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics
-
Sunagawa S., Higa F., Cash H.L., Tateyama M., Uno T., Fujita J. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respir. Viruses 2013, 7:1-3.
-
(2013)
Influenza Other Respir. Viruses
, vol.7
, pp. 1-3
-
-
Sunagawa, S.1
Higa, F.2
Cash, H.L.3
Tateyama, M.4
Uno, T.5
Fujita, J.6
-
194
-
-
78751692669
-
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza: a review
-
Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza: a review. Antivir. Chem. Chemother. 2010, 21:71-84.
-
(2010)
Antivir. Chem. Chemother.
, vol.21
, pp. 71-84
-
-
Yamashita, M.1
-
195
-
-
84880698280
-
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance
-
Kashiwagi S., Yoshida S., Yamaguchi H., Mitsui N., Tanigawa M., Shiosakai K., Yamanouchi N., Shiozawa T., Yamaguchi F. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. J. Infect. Chemother. 2013, 19:223-232.
-
(2013)
J. Infect. Chemother.
, vol.19
, pp. 223-232
-
-
Kashiwagi, S.1
Yoshida, S.2
Yamaguchi, H.3
Mitsui, N.4
Tanigawa, M.5
Shiosakai, K.6
Yamanouchi, N.7
Shiozawa, T.8
Yamaguchi, F.9
-
196
-
-
84930088282
-
-
Hovione http://www.hovione.com/twincaps/twincaps.asp.
-
-
-
-
198
-
-
59749091876
-
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity
-
Yamashita M., Tomozawa T., Kakuta M., et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 186-192
-
-
Yamashita, M.1
Tomozawa, T.2
Kakuta, M.3
-
199
-
-
78649456920
-
In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses
-
Kubo S., Kakuta M., Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses. Jpn. J. Antibiot. 2010, 63:337-346.
-
(2010)
Jpn. J. Antibiot.
, vol.63
, pp. 337-346
-
-
Kubo, S.1
Kakuta, M.2
Yamashita, M.3
-
200
-
-
69749088504
-
Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation
-
Kawai N., Ikematsu H., Iwaki N., et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 2009, 59:207-212.
-
(2009)
J. Infect.
, vol.59
, pp. 207-212
-
-
Kawai, N.1
Ikematsu, H.2
Iwaki, N.3
-
201
-
-
69149093400
-
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
-
Itoh Y., Shinya K., Kiso M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
-
(2009)
Nature
, vol.460
, pp. 1021-1025
-
-
Itoh, Y.1
Shinya, K.2
Kiso, M.3
-
202
-
-
84930085766
-
-
Biota http://investors.biotapharma.com/releasedetail.cfm?ReleaseID=863626.
-
-
-
-
203
-
-
77951470798
-
Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza
-
Wong J.P., Christopher M.E., Dai X., Schnell G., Stephen E.R., Van Loon D., Viswanathan S. Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. Expert Rev. Respir. Med. 2010, 4:171-184.
-
(2010)
Expert Rev. Respir. Med.
, vol.4
, pp. 171-184
-
-
Wong, J.P.1
Christopher, M.E.2
Dai, X.3
Schnell, G.4
Stephen, E.R.5
Van Loon, D.6
Viswanathan, S.7
-
204
-
-
57749187455
-
Developing new antiviral agents for influenza treatment: what does the future hold
-
Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold. Clin. Infect. Dis. 2009, 48:S3-S13.
-
(2009)
Clin. Infect. Dis.
, vol.48
, pp. S3-S13
-
-
Hayden, F.1
-
206
-
-
41149168072
-
Megaribavirin aerosol for the treatment of influenza A virus infections in mice
-
Gilbert B.E., McLeay M.T. Megaribavirin aerosol for the treatment of influenza A virus infections in mice. Antivir. Res. 2008, 78:223-229.
-
(2008)
Antivir. Res.
, vol.78
, pp. 223-229
-
-
Gilbert, B.E.1
McLeay, M.T.2
-
207
-
-
77954175831
-
Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice
-
Shi X.L., Shi Z.H., Huang H., Zhu H.G., Zhou P., Ju D. Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice. Inflammation 2009, 33:166-172.
-
(2009)
Inflammation
, vol.33
, pp. 166-172
-
-
Shi, X.L.1
Shi, Z.H.2
Huang, H.3
Zhu, H.G.4
Zhou, P.5
Ju, D.6
-
208
-
-
84355166782
-
Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model
-
Verreault D., Sivasubramani K.S., Talton J.D., Doyle A.L., Reddy J.D., Killeen S.Z., Didier P.J., Marx P.A., Roy C.J. Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model. Antivir. Res. 2012, 93:204-208.
-
(2012)
Antivir. Res.
, vol.93
, pp. 204-208
-
-
Verreault, D.1
Sivasubramani, K.S.2
Talton, J.D.3
Doyle, A.L.4
Reddy, J.D.5
Killeen, S.Z.6
Didier, P.J.7
Marx, P.A.8
Roy, C.J.9
-
209
-
-
80052011287
-
Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations
-
Pitman S.K., Drew R.H., Perfect J.R. Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opin. Emerg. Drugs 2011, 16:559-586.
-
(2011)
Expert Opin. Emerg. Drugs
, vol.16
, pp. 559-586
-
-
Pitman, S.K.1
Drew, R.H.2
Perfect, J.R.3
-
210
-
-
84864446193
-
Pulmonary fungal infections
-
Smith J.A., Kauffman C.A. Pulmonary fungal infections. Respirology 2012, 17:913-926.
-
(2012)
Respirology
, vol.17
, pp. 913-926
-
-
Smith, J.A.1
Kauffman, C.A.2
-
211
-
-
74949107171
-
Epidemiology of invasive mycoses in North America
-
Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010, 36:1-53.
-
(2010)
Crit. Rev. Microbiol.
, vol.36
, pp. 1-53
-
-
Pfaller, M.A.1
Diekema, D.J.2
-
212
-
-
78650794568
-
Thoracic soc fungal working, an official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients
-
Limper A.H., Knox K.S., Sarosi G.A., Ampel N.M., Bennett J.E., Catanzaro A., Davies S.F., Dismukes W.E., Hage C.A., Marr K.A., Mody C.H., Perfect J.R., Stevens D.A., Amer G. Thoracic soc fungal working, an official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 2011, 183:96-128.
-
(2011)
Am. J. Respir. Crit. Care Med.
, vol.183
, pp. 96-128
-
-
Limper, A.H.1
Knox, K.S.2
Sarosi, G.A.3
Ampel, N.M.4
Bennett, J.E.5
Catanzaro, A.6
Davies, S.F.7
Dismukes, W.E.8
Hage, C.A.9
Marr, K.A.10
Mody, C.H.11
Perfect, J.R.12
Stevens, D.A.13
Amer, G.14
-
213
-
-
79952186972
-
Aerosolised delivery of antifungal agents
-
Le J., Schiller D.S. Aerosolised delivery of antifungal agents. Curr. Fungal Infect. Rep. 2010, 4:96-102.
-
(2010)
Curr. Fungal Infect. Rep.
, vol.4
, pp. 96-102
-
-
Le, J.1
Schiller, D.S.2
-
214
-
-
84863495434
-
Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis
-
Hilberg O., Andersen C.U., Henning O., Lundby T., Mortensen J., Bendstrup E. Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis. Eur. Respir. J. 2012, 40:271-273.
-
(2012)
Eur. Respir. J.
, vol.40
, pp. 271-273
-
-
Hilberg, O.1
Andersen, C.U.2
Henning, O.3
Lundby, T.4
Mortensen, J.5
Bendstrup, E.6
-
215
-
-
85116178209
-
Use of aerosolised antifungals for the prophylaxis against and treatment of invasive pulmonary aspergillosis: climbing it because it is there?
-
Klepser M. Use of aerosolised antifungals for the prophylaxis against and treatment of invasive pulmonary aspergillosis: climbing it because it is there?. Pharm. Anal. Acta 2011, S1:e001.
-
(2011)
Pharm. Anal. Acta
, vol.S1
, pp. e001
-
-
Klepser, M.1
-
216
-
-
4143052855
-
Development of liposomal amphotericin B dry powder inhaler formulation
-
Shah S.P., Misra A. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv. 2004, 11:247-253.
-
(2004)
Drug Deliv.
, vol.11
, pp. 247-253
-
-
Shah, S.P.1
Misra, A.2
-
218
-
-
84865278282
-
Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity
-
Fauvel M., Farrugia C., Tsapis N., Gueutin C., Cabaret O., Bories C., Bretagne S., Barratt G. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity. Int. J. Pharm. 2012, 436:106-110.
-
(2012)
Int. J. Pharm.
, vol.436
, pp. 106-110
-
-
Fauvel, M.1
Farrugia, C.2
Tsapis, N.3
Gueutin, C.4
Cabaret, O.5
Bories, C.6
Bretagne, S.7
Barratt, G.8
-
219
-
-
78650061557
-
Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulisation
-
Gilani K., Moazeni E., Ramezanli T., Amini M., Fazeli M.R., Jamalifar H. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulisation. J. Pharm. Sci. 2011, 100:252-259.
-
(2011)
J. Pharm. Sci.
, vol.100
, pp. 252-259
-
-
Gilani, K.1
Moazeni, E.2
Ramezanli, T.3
Amini, M.4
Fazeli, M.R.5
Jamalifar, H.6
-
220
-
-
84861994530
-
The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection
-
Alsaadi M., Italia J.L., Mullen A.B., Kumar M., Candlish A.A., Williams R.A.M., Shaw C.D., Al Gawhari F., Coombs G.H., Wiese M., Thomson A.H., Puig-Sellart M., Wallace J., Sharp A., Wheeler L., Warn P., Carter K.C. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. J. Control. Release 2012, 160:685-691.
-
(2012)
J. Control. Release
, vol.160
, pp. 685-691
-
-
Alsaadi, M.1
Italia, J.L.2
Mullen, A.B.3
Kumar, M.4
Candlish, A.A.5
Williams, R.A.M.6
Shaw, C.D.7
Al Gawhari, F.8
Coombs, G.H.9
Wiese, M.10
Thomson, A.H.11
Puig-Sellart, M.12
Wallace, J.13
Sharp, A.14
Wheeler, L.15
Warn, P.16
Carter, K.C.17
-
221
-
-
84871918459
-
Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis
-
Rundfeldt C., Steckel H., Scherliess H., Wyska E., Wlaz P. Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. Eur. J. Pharm. Biopharm. 2013, 83:44-53.
-
(2013)
Eur. J. Pharm. Biopharm.
, vol.83
, pp. 44-53
-
-
Rundfeldt, C.1
Steckel, H.2
Scherliess, H.3
Wyska, E.4
Wlaz, P.5
-
222
-
-
84888198111
-
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
-
Andrade F., Rafael D., Videira M., Ferreira D., Sosnik A., Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 2013, 65:1816-1827.
-
(2013)
Adv. Drug Deliv. Rev.
, vol.65
, pp. 1816-1827
-
-
Andrade, F.1
Rafael, D.2
Videira, M.3
Ferreira, D.4
Sosnik, A.5
Sarmento, B.6
-
223
-
-
79957768993
-
Production methods for nanodrug particles using the bottom-up approach
-
Chan H.-K., Kwok P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
-
(2011)
Adv. Drug Deliv. Rev.
, vol.63
, pp. 406-416
-
-
Chan, H.-K.1
Kwok, P.C.L.2
-
225
-
-
77951652999
-
Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats
-
Yang W., Johnston K.P., Williams R.O. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur. J. Pharm. Biopharm. 2010, 75:33-41.
-
(2010)
Eur. J. Pharm. Biopharm.
, vol.75
, pp. 33-41
-
-
Yang, W.1
Johnston, K.P.2
Williams, R.O.3
-
226
-
-
84858748275
-
Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation
-
Jafarinejad S., Gilani K., Moazeni E., Ghazi-Khansari M., Najafabadi A.R., Mohajel N. Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation. Powder Technol. 2012, 222:65-70.
-
(2012)
Powder Technol.
, vol.222
, pp. 65-70
-
-
Jafarinejad, S.1
Gilani, K.2
Moazeni, E.3
Ghazi-Khansari, M.4
Najafabadi, A.R.5
Mohajel, N.6
-
227
-
-
84870316205
-
New inhalation-optimised itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis
-
Duret C., Wauthoz N., Sebti T., Vanderbist F., Amighi K. New inhalation-optimised itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int. J. Nanomedicine 2012, 7:5475-5489.
-
(2012)
Int. J. Nanomedicine
, vol.7
, pp. 5475-5489
-
-
Duret, C.1
Wauthoz, N.2
Sebti, T.3
Vanderbist, F.4
Amighi, K.5
-
228
-
-
84896738432
-
Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention
-
Duret C., Merlos R., Wauthoz N., Sebti T., Vanderbist F., Amighi K. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. Eur. J. Pharm. Biopharm. 2014, 86:46-54.
-
(2014)
Eur. J. Pharm. Biopharm.
, vol.86
, pp. 46-54
-
-
Duret, C.1
Merlos, R.2
Wauthoz, N.3
Sebti, T.4
Vanderbist, F.5
Amighi, K.6
-
229
-
-
84862832377
-
Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing
-
Beinborn N.A., Lirola H.L., Williams R.O. Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing. Int. J. Pharm. 2012, 429:46-57.
-
(2012)
Int. J. Pharm.
, vol.429
, pp. 46-57
-
-
Beinborn, N.A.1
Lirola, H.L.2
Williams, R.O.3
|